SEARCH

SEARCH BY CITATION

References

  • Andreasen P. A., Egelund R. and Petersen H. H. (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci. 57, 2540.
  • Anthony D. C., Ferguson B., Matyzak M. K., Miller K. M., Esiri M. M. and Perry V. H. (1997) Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 23, 406415.
  • Backstrom J. R., Miller C. A. and Tokes Z. A. (1992) Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J. Neurochem. 58, 983992.
  • Backstrom J. R., Lim G. P., Cullen M. J. and Tokes Z. A. (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1–40). J. Neurosci. 16, 79107919.
  • Birkedal-Hansen H., Moore W. G., Bodden M. K., Windsor L. J., Birkedal-Hansen B., De-Carlo A. and Engler J. A. (1993) Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 4, 197250.
  • Chandler S., Miller K. M., Clements J. M., Lury J., Corkill D., Anthony D. C., Adams S. E. and Gearing A. J. (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72, 155161.
  • Davis J. and Van Nostrand W. E. (1996) Enhanced pathologic properties of Dutch-type mutant amyloid β-protein. Proc. Natl Acad. Sci. USA 93, 29963000.
  • Davis J., Wagner M. R., Zhang W., Xu F. and Van Nostrand W. E. (2003) Amyloid β-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J. Biol. Chem. in press.
  • Davis-Salinas J., Saporito-Irwin S. M., Cotman C. W. and Van Nostrand W. E. (1995) Amyloid beta-protein induces its own production in cultured degenerating cerebrovascular smooth muscle cells. J. Neurochem. 65, 931934.
  • Deb S. and Gottschall P. E. (1996) Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J. Neurochem. 66, 16411647.
  • Frisch S. M. and Ruoslahti E. (1997) Integrins and anoikis. Curr. Opin. Cell Biol. 9, 701706.
  • Gijbels K., Masure S., Carton H. and Opdenakker G. (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41, 2934.
  • Howard E. W., Bullen E. C. and Banda M. J. (1991) Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. J. Biol. Chem. 266, 1307013075.
  • Janowska-Wieczorek A., Marquez L. A., Nabholtz J. M., Cabuhat M. L., Montano J., Chang H., Rozmus J., Russell J. A., Edwards D. R. and Turner A. R. (1999) Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood 93, 33793390.
  • Kawai M., Kalaria R. N., Cras P., Siedlak S. L., Velasco M. E., Shelton E. R., Chan H. W., Greenberg B. D. and Perry G. (1993) Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. Brain Res. 623, 142146.
  • Keski-Oja J., Lohi J., Tuuttila A., Tryggvason K. and Vartio T. (1992) Proteolytic processing of the 72,000 Da type IV collagenase by urokinase plasminogen activation. Exp. Cell Res. 202, 471476.
  • Kouwenhoven M., Carlstrom C., Ozenci V. and Link H. (2001) Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J. Clin. Immunol. 21, 365375.
  • Lewalle J. M., Munaut C., Pichot B., Cataldo D., Baramova E. and Foidart J. M. (1995) Plasma membrane-dependent activation of gelatinase A in human vascular endothelial cells. J. Cell Physiol. 165, 475483.
  • Li Z., Froehlich J., Galis Z. S. and Lakatta E. G. (1999) Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension 33, 116123.
  • Lim G. P., Backstrom J. R., Cullen M. J., Miller C. A., Atkinson R. D. and Tokes Z. A. (1996) Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J. Neurochem. 67, 251259.
  • Lim G. P., Russell M. J., Cullen M. J. and Tokes Z. A. (1997) Matrix metalloproteinases in dog brains exhibiting Alzheimer-like characteristics. J. Neurochem. 68, 16061611.
  • Melchor J. P. and Van Nostrand W. E. (2000) Fibrillar amyloid beta-protein mediates the pathologic accumulation of its secreted precursor in human cerebrovascular smooth muscle cells. J. Biol. Chem. 275, 97829791.
  • Mun-Bryce S. and Rosenberg G. A. (1998) Matrix metalloproteinases in cerebrovascular disease. J. Cerebr. Blood Flow Metabol. 18, 11631172.
  • Nagase H. (1997) Activation mechanisms of matrix metalloproteinases. Biol. Chem. 378, 151160.
  • Nagase H. and Woessner J. F. Jr (1999) Matrix metalloproteinases. J. Biol. Chem. 274, 2149121494.
  • Okada Y., Gonoji Y., Naka K., Tomita K., Nakanishi I., Iwata K., Yamashita K. and Hayakawa T. (1992) Matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase) from HT1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymatic properties. J. Biol. Chem. 267, 2171221719.
  • Overall C. M., Wrana J. L. and Sodek J. (1991) Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J. Biol. Chem. 266, 1406414071.
  • Planas A. M., Sole S. and Justicia C. (2001) Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol. Dis 8, 834846.
  • Romanic A. M., White R. F., Arleth A. J., Ohlstein E. H. and Barone F. C. (1998) Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29, 10201030.
  • Rosenberg G. A. (1995) Matrix metalloproteinases in brain injury. J. Neurotrauma 12, 833842.
  • Rosenberg G. A. and Navratil M. (1997) Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 48, 921926.
  • Rosenberg G. A., Mun-Bryce S., Wesley M. and Kornfeld M. (1990) Collagenase-induced intracerebral hemorrhage in rats. Stroke 21, 801807.
  • Rosenberg G. A., Kornfeld M., Estrada E., Kelley R. O., Liotta L. A. and Stetler-Stevenson W. G. (1992) TIMP-2 reduces proteolytic opening of blood–brain barrier by type IV collagenase. Brain Res. 576, 203207.
  • Rosenberg G. A., Estrada E., Kelley R. O. and Kornfeld M. (1993) Bacterial collagenase disrupts extracellular matrix and opens blood–brain barrier in rat. Neurosci. Lett. 160, 117119.
  • Rosenberg G. A., Estrada E. Y., Dencoff J. E. and Stetler-Stevenson W. G. (1995) Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood–brain barrier: an expanded therapeutic window. Brain Res. 703, 151155.
  • Rosenberg G. A., Navratil M., Barone F. and Feuerstein G. (1996) Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J. Cerebr. Blood Flow Metabol. 16, 360366.
  • Sakalihasan N., Delvenne P., Nusgens B. V., Limet R. and Lapiere C. M. (1996) Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J. Vasc. Surg. 24, 127133.
  • Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E. and Seiki M. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 6165.
  • Shofuda K., Yasumitsu H., Nishihashi A., Miki K. and Miyazaki K. (1997) Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain. J. Biol. Chem. 272, 97499754.
  • Shofuda K., Nagashima Y., Kawahara K., Yasumitsu H., Miki K. and Miyazaki K. (1998) Elevated expression of membrane-type 1 and 3 matrix metalloproteinases in rat vascular smooth muscle cells activated by arterial injury. Lab. Invest. 78, 915923.
  • Springman E. B., Angleton E. L., Birkedal-Hansen H. and Van Wart H. E. (1990) Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a ‘cysteine switch’ mechanism for activation. Proc. Natl Acad. Sci. USA 87, 364368.
  • Stetler-Stevenson W. G., Aznavoorian S. and Liotta L. A. (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9, 541573.
  • Strongin A. Y., Collier I., Bannikov G., Marmer B. L., Grant G. A. and Goldberg G. I. (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270, 53315338.
  • Takino T., Sato H., Shinagawa A. and Seiki M. (1995) Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J. Biol. Chem. 270, 2301323020.
  • Uhm J. H., Dooley N. P., Villemure J. G. and Yong V. W. (1997) Mechanisms of glioma invasion: role of matrix-metalloproteinases. Can. J. Neurol. Sci. 24, 315.
  • Van Nostrand W. E., Rozemuller A. J., Chung R., Cotman C. W. and Saporito-Irwin S. M. (1994) Amyloid beta-protein precursor in cultured leptomeningeal smooth muscle cells. Amyloid 1, 17.
  • Van Nostrand W. E., Melchor J. P. and Ruffini L. (1998) Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J. Neurochem. 70, 216223.
  • Van Wart H. E. and Birkedal-Hansen H. (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl Acad. Sci. USA 87, 55785582.
  • Vinters H. V. (1987) Cerebral amyloid angiopathy. A critical review. Stroke 18, 311324.
  • Wattendorff A. R., Frangione B., Luyendijk W. and Bots G. T. A. M. (1995) Hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D): clinicopathological studies. J. Neurol. Neurosurg. Psychiat. 59, 699705.
  • Yong V. W., Krekoski C. A., Forsyth P. A., Bell R. and Edwards D. R. (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21, 7580.
  • Yong V. W., Power C., Forsyth P. and Edwards D. R. (2001) Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2, 502511.
  • Yu M., Sato H., Seiki M. and Thompson E. W. (1995) Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res. 55, 32723277.
  • Zucker S., Drews M., Conner C., Foda H. D., DeClerck Y. A., Langley K. E., Bahou W. F., Docherty A. J. and Cao J. (1998) Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J. Biol. Chem. 273, 12161222.